Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15634802 | 0.89 | CCR8 (0.68) | CCR8KDM4ES1PR5MEN1KMT2A | |
| SCHEMBL15635404 | 0.89 | CCR8 (0.68) | CCR8KDM4ES1PR5MEN1KMT2A | |
| SCHEMBL17099412 | 0.88 | CCR8 (0.62) | CCR8KDM4EDRD2S1PR5MEN1 | |
| SCHEMBL17048485 | 0.88 | CCR8 (0.65) | CCR8KDM4EDRD2S1PR5MEN1 | |
| SCHEMBL17104843 | 0.88 | CCR8 (0.67) | CCR8KDM4ES1PR5MEN1KMT2A | |
| SCHEMBL17099425 | 0.86 | CCR8 (0.59) | CCR8KDM4ES1PR5ALDH1A1 | |
| SCHEMBL17099426 | 0.85 | CCR8 (0.61) | CCR8KDM4ES1PR1S1PR5MEN1 | |
| SCHEMBL17099350 | 0.85 | KDM4E (0.62) | CCR8KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL17099387 | 0.85 | CCR8 (0.63) | CCR8KDM4ES1PR1S1PR5MEN1 | |
| SCHEMBL17099422 | 0.84 | CCR8 (0.62) | CCR8KDM4ES1PR1S1PR5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | CCR8 3573/4885KDM4E 2066/4885S1PR1 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.